

REFERENCES

- Ahlawat, R. and D’cruz, S. (2016). Drug Utilization Pattern in Chronic Kidney Disease Patients at a Tertiary Care Public Teaching Hospital: Evidence from a Cross- Sectional Study. *Journal of Pharmaceutical Care & Health Systems*, 03(01). doi:10.4172/2376-0419.1000149.
- Ashok, P., and Subramanian, V. T. (2017). Importance of Drug Utilization Evaluation Studies In Patient Health Care. *Indian Journal of Pharmacy Practice*. 10(3), pp.157-159.
- Balakumar, P., Rohilla, A. and Thangathirupathi, A. (2010). Gentamicin-induced nephrotoxicity: Do we have a promising therapeutic approach to blunt it? *Pharmacological Research*, 62(3), pp.179–186. doi:10.1016/j.phrs.2010.04.004.
- Barsoum, R. S. (2006). Chronic kidney disease in the developing world. *N Engl J Med*, 354(10), pp. 997-999.
- Bracamonte, H. (2013). *Albumin and Chronic Kidney Disease*. [online] Dialysis Patient Citizens Education Center. Available at: <https://www.dpcedcenter.org/news-events/news/albumin-and-chronic-kidney-disease/#:~:text=Albumin%20provides%20the%20body%20with> [Accessed 13 Oct. 2022].
- CDC (2021). *Chronic Kidney Disease in the United States, 2021*. [online] www.cdc.gov. Available at: <https://www.cdc.gov/kidneydisease/publications-resources/ckd-national-facts.html>.
- CDC (2022). *Chronic Kidney Disease in the United States, 2021*. [online] www.cdc.gov. Available at: <https://www.cdc.gov/kidneydisease/publications-resources/ckd-national-facts.html#> [Accessed 16 Sep. 2022].
- Chang, C.-H., Fan, P.-C., Kuo, G., Lin, Y.-S., Tsai, T.-Y., Chang, S.-W., Tian, Y.-C. and Lee, C.-C. (2020). Infection in Advanced Chronic Kidney Disease and Subsequent Adverse Outcomes after Dialysis Initiation: A Nationwide Cohort Study. *Scientific Reports*, 10(1). doi:10.1038/s41598-020-59794-7.
- Garner, A. and Fadlallah, H. (1997). Pantoprazole: a new and more specific proton pump inhibitor. *Expert Opinion on Investigational Drugs*, 6(7), pp.885–893. doi:10.1517/13543784.6.7.885.
- Hill, N.R., Fatoba, S.T., Oke, J.L., Hirst, J.A., O’Callaghan, C.A., Lasserson, D.S. and Hobbs, F.D.R. (2016). Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis. *PLOS ONE*, [online] 11(7), p.e0158765. doi:10.1371/journal.pone.0158765.

- Indriani, L., Bahtiar, A., and Andrajati, R. (2013). Drug Related Problems Evaluation of Chronic Kidney Disease Patients in Inpatient Department of Fatmawati General Hospital., *Journal of Management and Pharmacy Practice* 3(1). pp.39-45.
- Kamath, A. and Pemminati, S. (2017). Methylcobalamin in vitamin B12 deficiency: To give or not to give? *Journal of Pharmacology and Pharmacotherapeutics*, 8(1), p.33. doi:10.4103/jpp.jpp_173_16.
- Kanani, N.J., Mistry, V.R. and Rathva, S.J. (2019). Drug utilization pattern in chronic kidney disease patients at a tertiary care teaching hospital. *Innovations in Pharmaceuticals and Pharmacotherapy*, 7(2), pp.31–36.
- KDIGO (2012). KDIGO 2012 Clinical Practice Guideline for Anemia in Chronic Kidney Disease. *Kidney International*, 2(4).
- KDIGO (2013). KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney International*, (3)1.
- KDIGO (2017). KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (SKD-MBD). *Kidney International*, 7(1).
- KDIGO (2021). KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. *Kidney International*, 99(3S).
- Kementrian Kesehatan RI (2017). Situasi Penyakit Ginjal Kronis. *Infodatin*.
- Kementrian Kesehatan RI (2019) *LAPORAN NASIONAL RISKESDAS 2018*. Jakarta: Badan Penelitian dan Pengembangan Kesehatan.
- Koppe, L., Cassani de Oliveira, M. and Fouque, D. (2019). Ketoacid Analogues Supplementation in Chronic Kidney Disease and Future Perspectives. *Nutrients*, 11(9), p.2071. doi:10.3390/nu11092071.
- Kovesdy, C.P. (2022). Epidemiology of chronic kidney disease: an update 2022. *Kidney International Supplements*, 12(1), pp.7–11. doi:10.1016/j.kisu.2021.11.003.
- Koyama, K. (2002). Efficacy of methylcobalamin on lowering total homocysteine plasma concentrations in haemodialysis patients receiving high-dose folic acid supplementation. *Nephrology Dialysis Transplantation*, 17(5), pp.916–922. doi:10.1093/ndt/17.5.916.
- Laporte, J. R. and Orme, M. L. (1993). Drug utilization and the teaching of rational drug use. In: Dukes, M.N.G. ed. *Drug Utilization Studies: Methods and Uses*, Finland: World Health Organization, pp. 183-191.

LKPP (2015). *Peraturan Kepala Lembaga Kebijakan Pengadaan Barang/Jasa Pemerintah Nomor 14 Tahun 2015 tentang E-Purchasing*.

MacRae, C., Mercer, S.W., Guthrie, B. and Henderson, D. (2020). Comorbidity in chronic kidney disease: a large cross-sectional study of prevalence in Scottish primary care. *British Journal of General Practice*, 71(704), pp.e243–e249. doi:10.3399/bjgp20x714125.

Merz, C.N.B., Dember, L.M., Ingelfinger, J.R., Vinson, A., Neugarten, J., Sandberg, K.L., Sullivan, J.C., Maric-Bilkan, C., Rankin, T.L., Kimmel, P.L. and Star, R.A. (2019). Sex and the kidneys: current understanding and research opportunities. *Nature reviews. Nephrology*, [online] 15(12), pp.776–783. doi:10.1038/s41581-019-0208-6.

Minister of Health Republic of Indonesia (2016). *Peraturan Menteri Kesehatan Republik Indonesia Nomor 76 tahun 2016 tentang Pedoman Indonesian Case Base Groups (INA-CBG) dalam Pelaksanaan Jaminan Kesehatan Nasional*.

Minister of Health Republic of Indonesia (2017) *Pedoman Nasional Pelayanan Kedokteran Tata Laksana Penyakit Ginjal Tahap Akhir*.

Minister of Health Republic of Indonesia (2017). *Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/659/2017 tentang Formularium Nasional*.

Minister of Health Republic of Indonesia (2021). *Keputusan Menteri Kesehatan Republik Nomor HK.01.07/Menkes/6485/2021 tentang Formularium Nasional*.

Morishita, Y., Numata, A., Miki, A., Okada, M., Ishibashi, K., Takemoto, F., Ando, Y., Muto, S. and Kusano, E. (2013). Medication-prescribing patterns of primary care physicians in chronic kidney disease. *Clinical and Experimental Nephrology*, 18(5), pp.690–696. doi:10.1007/s10157-013-0903-8.

National Kidney Foundation (2017) *Chronic Kidney Disease (CKD) Symptoms and causes*. [online]. National Kidney Foundation. Available at: <https://www.kidney.org/atoz/content/about-chronic-kidney-disease> [Accessed: 28 Aug. 2021]

National Kidney Foundation (2021). *Mineral and Bone Disorder*. [online] National Kidney Foundation. Available at: <https://www.kidney.org/atoz/content/MineralBoneDisorder>.

Nayak-Rao, S. (2010). Aminoglycoside use in renal failure. *Indian Journal of Nephrology*, [online] 20(3), pp.121–124. doi:10.4103/0971-4065.70839.

- Payne, R. A., and Avery, A. J. (2011). Polypharmacy: one of the greatest prescribing challenges in general practice. *British Journal of General Practice*. pp. 83-84.
- Sakinah (2020). *Drug Utilization Study In Geriatri Patients With Chronic Kidney Disease*. Undergraduate Thesis.
- Satirapoj, B., Vongwattana, P. and Supasynhd, O. (2018). Very low protein diet plus ketoacid analogs of essential amino acids supplement to retard chronic kidney disease progression. *Kidney Research and Clinical Practice*, 37(4), pp.384–392. doi:10.23876/j.krcp.18.0055.
- Shah, P.B., Soundararajan, P., Sathiyasekaran, B.W. and Hegde, S.C. (2017). Diuretics for people with chronic kidney disease. *Cochrane Database of Systematic Reviews*, [online] 10. doi:10.1002/14651858.cd011339.pub2.
- Sica, D.A. (2011). Diuretic use in renal disease. *Nature Reviews Nephrology*, 8(2), pp.100–109. doi:10.1038/nrneph.2011.175.
- TNP2K (2020). *Kajian Kebijakan Pengadaan Obat untuk program Jaminan Kesehatan Nasional 2014 - 2018*. Available at: [https://www.tnp2k.go.id/download/29882Kajian%20Kebijakan%20Obat%202014-2018%2026%20Juni%202020%20\(1\).pdf](https://www.tnp2k.go.id/download/29882Kajian%20Kebijakan%20Obat%202014-2018%2026%20Juni%202020%20(1).pdf).
- UK Kidney Association (n.d). *CKD Stages G4 and G5*. [online] UK Kidney Association. Available at: <https://ukkidney.org/health-professionals/information-resources/uk-eckd-guide/ckd-stages-g4-and-g5> [Accessed: 28 Aug. 2021]
- Wong, C.W. (2017). Vitamin B12 Deficiency in the Elderly. *Nutrition and Functional Foods for Healthy Aging*, pp.159–166. doi:10.1016/b978-0-12-805376-8.00016-2.
- World Health Organization (2003). *Introduction to Drug Utilization Research*. Oslo: World Health Organization.
- World Health Organization (2016). *ICD-10 Version:2016*. [online] icd.who.int. Available at: <https://icd.who.int/browse10/2016/en/#/> [Accessed 17 Nov. 2022].
- World Health Organization (2019). *Medication Safety in Polypharmacy* Geneva: World Health Organization.
- World Health Organization (n.d.). *Anatomical Therapeutic Chemical (ATC) Classification*. [online] www.who.int. Available at: <https://www.who.int/tools/atc-ddd-toolkit/atc-classification>.

Vos, T., Lim, S.S., Abbafati, C., Abbas, K.M., Abbasi, M., Abbasifard, M., Abbasi-Kangevari, M., Abbastabar, H., Abd-Allah, F., Abdelalim, A., Abdollahi, M., Abdollahpour, I., Abolhassani, H., Aboyans, V., Abrams, E.M., Abreu, L.G., Abrigo, M.R.M., Abu-Raddad, L.J., Abushouk, A.I. and Acebedo, A. (2020). Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *The Lancet*, [online] 396(10258), pp.1204–1222. Available at: [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(20\)30925-9/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30925-9/fulltext).